{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:24:49Z","timestamp":1787063089602,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1743-422x-10-349","type":"journal-article","created":{"date-parts":[[2013,12,4]],"date-time":"2013-12-04T21:05:21Z","timestamp":1386191121000},"source":"Crossref","is-referenced-by-count":57,"title":["Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice"],"prefix":"10.1186","volume":"10","author":[{"given":"George M","family":"Warimwe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Lopez-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Reyes-Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G","family":"Cottingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra J","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine A","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew DJ","family":"Dicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Milicic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Lall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Furze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison V","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian VS","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,5]]},"reference":[{"key":"2335_CR1","volume-title":"Mapping of poverty and likely zoonoses hotspots (zoonoses project 4)","author":"ILRI","year":"2012","unstructured":"ILRI: Mapping of poverty and likely zoonoses hotspots (zoonoses project 4). United Kingdom: Report to Department for International Development; 2012. http:\/\/www.dfid.gov.uk\/r4d\/Output\/190314\/Default.aspx"},{"key":"2335_CR2","doi-asserted-by":"publisher","first-page":"e1475","DOI":"10.1371\/journal.pntd.0001475","volume":"6","author":"PJ Hotez","year":"2012","unstructured":"Hotez PJ, Savioli L, Fenwick A: Neglected tropical diseases of the Middle East and North Africa: review of their prevalence, distribution, and opportunities for control. PLoS Negl Trop Dis 2012, 6: e1475. 10.1371\/journal.pntd.0001475","journal-title":"PLoS Negl Trop Dis"},{"key":"2335_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/path.1700340418","volume":"34","author":"R Daubney","year":"1931","unstructured":"Daubney R, Hudson JR, Granham PC: Enzootic Hepatitis or Rift Valley fever: an undescribed virus disease of sheep, cattle and man from East Africa. J Pathol Bacteriol 1931, 34: 545-579. 10.1002\/path.1700340418","journal-title":"J Pathol Bacteriol"},{"key":"2335_CR4","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1016\/j.vaccine.2010.04.085","volume":"28","author":"B Dungu","year":"2010","unstructured":"Dungu B, Louw I, Lubisi A, Hunter P, von Teichman BF, Bouloy M: Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep. Vaccine 2010, 28: 4581-4587. 10.1016\/j.vaccine.2010.04.085","journal-title":"Vaccine"},{"key":"2335_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3181\/00379727-64-15803","volume":"64","author":"AB Sabin","year":"1947","unstructured":"Sabin AB, Blumberg RW: Human infection with Rift Valley fever virus and immunity twelve years after single attack. Proc Soc Exp Biol Med 1947, 64: 385-389. 10.3181\/00379727-64-15803","journal-title":"Proc Soc Exp Biol Med"},{"key":"2335_CR6","volume-title":"Ordinary meeting of the Royal Society; December 10","author":"GM Findlay","year":"1931","unstructured":"Findlay GM Rift valley fever or enzootic hepatitis. In Ordinary meeting of the Royal Society; December 10. Keppel Street, London: London School of Hygiene and Tropical Medicine; 1931."},{"key":"2335_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(57)92243-2","volume":"270","author":"RD Brown","year":"1957","unstructured":"Brown RD, Scott GR, Dalling T: Persistence of antibodies to Rift Valley Fever in man. Lancet 1957, 270: 345.","journal-title":"Lancet"},{"key":"2335_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/BF01241162","volume":"4","author":"GM Findlay","year":"1951","unstructured":"Findlay GM, Howard EM: Notes on Rift Valley fever. Arch Gesamte Virusforsch 1951, 4: 411-423. 10.1007\/BF01241162","journal-title":"Arch Gesamte Virusforsch"},{"key":"2335_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/0042-6822(85)90320-4","volume":"144","author":"MS Collett","year":"1985","unstructured":"Collett MS, Purchio AF, Keegan K, Frazier S, Hays W, Anderson DK, Parker MD, Schmaljohn C, Schmidt J, Dalrymple JM: Complete nucleotide sequence of the M RNA segment of Rift Valley fever virus. Virology 1985, 144: 228-245. 10.1016\/0042-6822(85)90320-4","journal-title":"Virology"},{"key":"2335_CR10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1128\/JVI.58.2.263-270.1986","volume":"58","author":"K Keegan","year":"1986","unstructured":"Keegan K, Collett MS: Use of bacterial expression cloning to define the amino acid sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus. J Virol 1986, 58: 263-270.","journal-title":"J Virol"},{"key":"2335_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/0042-6822(89)90365-6","volume":"170","author":"CS Schmaljohn","year":"1989","unstructured":"Schmaljohn CS, Parker MD, Ennis WH, Dalrymple JM, Collett MS, Suzich JA, Schmaljohn AL: Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology 1989, 170: 184-192. 10.1016\/0042-6822(89)90365-6","journal-title":"Virology"},{"key":"2335_CR12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fcimb.2012.00131","volume":"2","author":"SV Indran","year":"2012","unstructured":"Indran SV, Ikegami T: Novel approaches to develop Rift Valley fever vaccines. Front Cell Infect Microbiol 2012, 2: 131.","journal-title":"Front Cell Infect Microbiol"},{"key":"2335_CR13","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1038\/mt.2012.223","volume":"20","author":"SH Sheehy","year":"2012","unstructured":"Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, Collins KA, Edwards NJ, Douglas AD, Anagnostou NA, et al.: ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther 2012, 20: 2355-2368. 10.1038\/mt.2012.223","journal-title":"Mol Ther"},{"key":"2335_CR14","doi-asserted-by":"publisher","first-page":"7306","DOI":"10.1016\/j.vaccine.2010.08.077","volume":"28","author":"S Howles","year":"2010","unstructured":"Howles S, Guimaraes-Walker A, Yang H, Hancock G, di Gleria K, Tarragona-Fiol T, Hayes P, Gilmour J, Bridgeman A, Hanke T, et al.: Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects. Vaccine 2010, 28: 7306-7312. 10.1016\/j.vaccine.2010.08.077","journal-title":"Vaccine"},{"key":"2335_CR15","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1164\/rccm.201108-1548OC","volume":"185","author":"TJ Scriba","year":"2012","unstructured":"Scriba TJ, Tameris M, Smit E, van der Merwe L, Hughes EJ, Kadira B, Mauff K, Moyo S, Brittain N, Lawrie A, et al.: A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and\/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med 2012, 185: 769-778. 10.1164\/rccm.201108-1548OC","journal-title":"Am J Respir Crit Care Med"},{"key":"2335_CR16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1126\/scitranslmed.3003155","volume":"4","author":"E Barnes","year":"2012","unstructured":"Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, et al.: Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012, 4: 115. ra111","journal-title":"Sci Transl Med"},{"key":"2335_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/cid\/cis327","volume":"55","author":"PJ Lillie","year":"2012","unstructured":"Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais ME, Duncan CJ, et al.: Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP\u2009+\u2009M1, in humans. Clin Infect Dis 2012, 55: 19-25. 10.1093\/cid\/cis327","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"2335_CR18","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1038\/sj.gt.3302618","volume":"12","author":"TB Ferreira","year":"2005","unstructured":"Ferreira TB, Alves PM, Aunins JG, Carrondo MJ: Use of adenoviral vectors as veterinary vaccines. Gene Ther 2005,12(Suppl 1):S73-S83.","journal-title":"Gene Ther"},{"key":"2335_CR19","doi-asserted-by":"publisher","first-page":"e37170","DOI":"10.1371\/journal.pone.0037170","volume":"7","author":"J Qin","year":"2012","unstructured":"Qin J, Huang H, Ruan Y, Hou X, Yang S, Wang C, Huang G, Wang T, Feng N, Gao Y, Xia X: A novel recombinant Peste des petits ruminants-canine adenovirus vaccine elicits long-lasting neutralizing antibody response against PPR in goats. PLoS One 2012, 7: e37170. 10.1371\/journal.pone.0037170","journal-title":"PLoS One"},{"key":"2335_CR20","doi-asserted-by":"publisher","first-page":"e52513","DOI":"10.1371\/journal.pone.0052513","volume":"7","author":"V Contreras","year":"2012","unstructured":"Contreras V, Urien C, Jouneau L, Bourge M, Bouet-Cararo C, Bonneau M, Zientara S, Klonjkowski B, Schwartz-Cornil I: Canine recombinant adenovirus vector induces an immunogenicity-related gene expression profile in skin-migrated CD11b(+) -type DCs. PLoS One 2012, 7: e52513. 10.1371\/journal.pone.0052513","journal-title":"PLoS One"},{"key":"2335_CR21","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1128\/CVI.00275-12","volume":"19","author":"B Perez de Val","year":"2012","unstructured":"Perez de Val B, Villarreal-Ramos B, Nofrarias M, Lopez-Soria S, Romera N, Singh M, Abad FX, Xing Z, Vordermeier HM, Domingo M: Goats primed with Mycobacterium bovis BCG and boosted with a recombinant adenovirus expressing Ag85A show enhanced protection against tuberculosis. Clin Vaccine Immunol 2012, 19: 1339-1347. 10.1128\/CVI.00275-12","journal-title":"Clin Vaccine Immunol"},{"key":"2335_CR22","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1128\/IAI.00287-09","volume":"77","author":"HM Vordermeier","year":"2009","unstructured":"Vordermeier HM, Villarreal-Ramos B, Cockle PJ, McAulay M, Rhodes SG, Thacker T, Gilbert SC, McShane H, Hill AV, Xing Z, Hewinson RG: Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 2009, 77: 3364-3373. 10.1128\/IAI.00287-09","journal-title":"Infect Immun"},{"issue":"Pt 3","key":"2335_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1099\/0022-1317-80-3-671","volume":"80","author":"A Sanz-Parra","year":"1999","unstructured":"Sanz-Parra A, Vazquez B, Sobrino F, Cox SJ, Ley V, Salt JS: Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of foot-and-mouth disease virus capsid proteins. J Gen Virol 1999,80(Pt 3):671-679.","journal-title":"J Gen Virol"},{"key":"2335_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.biologicals.2005.08.009","volume":"33","author":"MJ Grubman","year":"2005","unstructured":"Grubman MJ: Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals. Biologicals 2005, 33: 227-234. 10.1016\/j.biologicals.2005.08.009","journal-title":"Biologicals"},{"key":"2335_CR25","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1128\/JVI.70.6.3770-3780.1996","volume":"70","author":"JM Torres","year":"1996","unstructured":"Torres JM, Alonso C, Ortega A, Mittal S, Graham F, Enjuanes L: Tropism of human adenovirus type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus. J Virol 1996, 70: 3770-3780.","journal-title":"J Virol"},{"key":"2335_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1046\/j.1365-3024.1997.d01-200.x","volume":"19","author":"JS Rothel","year":"1997","unstructured":"Rothel JS, Boyle DB, Both GW, Pye AD, Waterkeyn JG, Wood PR, Lightowlers MW: Sequential nucleic acid and recombinant adenovirus vaccination induces host-protective immune responses against Taenia ovis infection in sheep. Parasite Immunol 1997, 19: 221-227. 10.1046\/j.1365-3024.1997.d01-200.x","journal-title":"Parasite Immunol"},{"issue":"Pt 5","key":"2335_CR27","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1099\/0022-1317-80-5-1263","volume":"80","author":"AN Zakhartchouk","year":"1999","unstructured":"Zakhartchouk AN, Pyne C, Mutwiri GK, Papp Z, Baca-Estrada ME, Griebel P, Babiuk LA, Tikoo SK: Mucosal immunization of calves with recombinant bovine adenovirus-3: induction of protective immunity to bovine herpesvirus-1. J Gen Virol 1999,80(Pt 5):1263-1269.","journal-title":"J Gen Virol"},{"key":"2335_CR28","doi-asserted-by":"publisher","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","volume":"7","author":"MD Dicks","year":"2012","unstructured":"Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, Hill AV, Cottingham MG: A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 2012, 7: e40385. 10.1371\/journal.pone.0040385","journal-title":"PLoS One"},{"key":"2335_CR29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1126\/scitranslmed.3002925","volume":"4","author":"S Colloca","year":"2012","unstructured":"Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani L, Naddeo M, Grazioli F, Esposito ML, et al.: Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012, 4: 115. ra112","journal-title":"Sci Transl Med"},{"key":"2335_CR30","doi-asserted-by":"publisher","first-page":"e1000503","DOI":"10.1371\/journal.ppat.1000503","volume":"5","author":"S Roy","year":"2009","unstructured":"Roy S, Vandenberghe LH, Kryazhimskiy S, Grant R, Calcedo R, Yuan X, Keough M, Sandhu A, Wang Q, Medina-Jaszek CA, et al.: Isolation and characterization of adenoviruses persistently shed from the gastrointestinal tract of non-human primates. PLoS Pathog 2009, 5: e1000503. 10.1371\/journal.ppat.1000503","journal-title":"PLoS Pathog"},{"key":"2335_CR31","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1128\/CVI.00182-09","volume":"16","author":"DH Holman","year":"2009","unstructured":"Holman DH, Penn-Nicholson A, Wang D, Woraratanadharm J, Harr MK, Luo M, Maher EM, Holbrook MR, Dong JY: A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity. Clin Vaccine Immunol 2009, 16: 1624-1632. 10.1128\/CVI.00182-09","journal-title":"Clin Vaccine Immunol"},{"key":"2335_CR32","doi-asserted-by":"publisher","first-page":"8049","DOI":"10.1016\/j.vaccine.2011.08.042","volume":"29","author":"RJ Cox","year":"2011","unstructured":"Cox RJ, Pedersen G, Madhun AS, Svindland S, Saevik M, Breakwell L, Hoschler K, Willemsen M, Campitelli L, Nostbakken JK, et al.: Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial. Vaccine 2011, 29: 8049-8059. 10.1016\/j.vaccine.2011.08.042","journal-title":"Vaccine"},{"key":"2335_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/erv.12.140","volume":"12","author":"DT O\u2019Hagan","year":"2013","unstructured":"O\u2019Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD: The history of MF59((R)) adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines 2013, 12: 13-30. 10.1586\/erv.12.140","journal-title":"Expert Rev Vaccines"},{"key":"2335_CR34","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1750-2659.2011.00256.x","volume":"5","author":"G Pedersen","year":"2011","unstructured":"Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ: Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respir Viruses 2011, 5: 426-437. 10.1111\/j.1750-2659.2011.00256.x","journal-title":"Influenza Other Respir Viruses"},{"key":"2335_CR35","doi-asserted-by":"publisher","first-page":"e79194","DOI":"10.1371\/journal.pone.0079194","volume":"8","author":"PH Goff","year":"2013","unstructured":"Goff PH, Eggink D, Seibert CW, Hai R, Martinez-Gil L, Krammer F, Palese P: Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One 2013, 8: e79194. 10.1371\/journal.pone.0079194","journal-title":"PLoS One"},{"key":"2335_CR36","doi-asserted-by":"publisher","first-page":"7367","DOI":"10.1016\/j.vaccine.2009.09.044","volume":"27","author":"AS Madhun","year":"2009","unstructured":"Madhun AS, Haaheim LR, Nilsen MV, Cox RJ: Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine 2009, 27: 7367-7376. 10.1016\/j.vaccine.2009.09.044","journal-title":"Vaccine"},{"key":"2335_CR37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.chom.2008.12.004","volume":"5","author":"SJ Draper","year":"2009","unstructured":"Draper SJ, Goodman AL, Biswas S, Forbes EK, Moore AC, Gilbert SC, Hill AV: Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria. Cell Host Microbe 2009, 5: 95-105. 10.1016\/j.chom.2008.12.004","journal-title":"Cell Host Microbe"},{"key":"2335_CR38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1586\/erv.13.15","volume":"12","author":"S Capone","year":"2013","unstructured":"Capone S, D\u2019Alise AM, Ammendola V, Colloca S, Cortese R, Nicosia A, Folgori A: Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines 2013, 12: 379-393. 10.1586\/erv.13.15","journal-title":"Expert Rev Vaccines"},{"key":"2335_CR39","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1016\/j.vaccine.2009.03.080","volume":"27","author":"M Dudareva","year":"2009","unstructured":"Dudareva M, Andrews L, Gilbert SC, Bejon P, Marsh K, Mwacharo J, Kai O, Nicosia A, Hill AV: Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 2009, 27: 3501-3504. 10.1016\/j.vaccine.2009.03.080","journal-title":"Vaccine"},{"key":"2335_CR40","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","volume":"372","author":"SP Buchbinder","year":"2008","unstructured":"Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al.: Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372: 1881-1893. 10.1016\/S0140-6736(08)61591-3","journal-title":"Lancet"},{"key":"2335_CR41","first-page":"107","volume":"135","author":"A Ludi","year":"2013","unstructured":"Ludi A, Rodriguez L: Novel approaches to foot-and-mouth disease vaccine development. Dev Biol (Basel) 2013, 135: 107-116.","journal-title":"Dev Biol (Basel)"},{"key":"2335_CR42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.antiviral.2009.08.002","volume":"84","author":"M Bouloy","year":"2009","unstructured":"Bouloy M, Flick R: Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines. Antiviral Res 2009, 84: 101-118. 10.1016\/j.antiviral.2009.08.002","journal-title":"Antiviral Res"},{"key":"2335_CR43","doi-asserted-by":"publisher","first-page":"6161","DOI":"10.1128\/JVI.00337-13","volume":"87","author":"KA Dodd","year":"2013","unstructured":"Dodd KA, McElroy AK, Jones ME, Nichol ST, Spiropoulou CF: Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses. J Virol 2013, 87: 6161-6171. 10.1128\/JVI.00337-13","journal-title":"J Virol"},{"key":"2335_CR44","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1371\/journal.pntd.0002309","volume":"7","author":"E Lopez-Gil","year":"2013","unstructured":"Lopez-Gil E, Lorenzo G, Hevia E, Borrego B, Eiden M, Groschup M, Gilbert SC, Brun A: A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8\u2009+\u2009-T cell activation and protects immune-competent mice against a lethal RVFV infection. PLoS Negl Trop Dis 2013, 7: e2309. 10.1371\/journal.pntd.0002309","journal-title":"PLoS Negl Trop Dis"},{"issue":"Pt 10","key":"2335_CR45","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","volume":"66","author":"H Caplen","year":"1985","unstructured":"Caplen H, Peters CJ, Bishop DH: Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 1985,66(Pt 10):2271-2277.","journal-title":"J Gen Virol"},{"key":"2335_CR46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","volume":"36","author":"FL Graham","year":"1977","unstructured":"Graham FL, Smiley J, Russell WC, Nairn R: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977, 36: 59-74. 10.1099\/0022-1317-36-1-59","journal-title":"J Gen Virol"},{"key":"2335_CR47","doi-asserted-by":"publisher","first-page":"e20977","DOI":"10.1371\/journal.pone.0020977","volume":"6","author":"S Biswas","year":"2011","unstructured":"Biswas S, Dicks MD, Long CA, Remarque EJ, Siani L, Colloca S, Cottingham MG, Holder AA, Gilbert SC, Hill AV, Draper SJ: Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. PLoS One 2011, 6: e20977. 10.1371\/journal.pone.0020977","journal-title":"PLoS One"},{"key":"2335_CR48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0165-2478(90)90086-6","volume":"25","author":"P Romero","year":"1990","unstructured":"Romero P, Maryanski JL, Cordey AS, Corradin G, Nussenzweig RS, Zavala F: Isolation and characterization of protective cytolytic T cells in a rodent malaria model system. Immunol Lett 1990, 25: 27-31. 10.1016\/0165-2478(90)90086-6","journal-title":"Immunol Lett"},{"key":"2335_CR49","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/mt.2012.25","volume":"20","author":"A Reyes-Sandoval","year":"2012","unstructured":"Reyes-Sandoval A, Rollier CS, Milicic A, Bauza K, Cottingham MG, Tang CK, Dicks MD, Wang D, Longley RJ, Wyllie DH, Hill AV: Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity. Mol Ther 2012, 20: 1633-1647. 10.1038\/mt.2012.25","journal-title":"Mol Ther"},{"key":"2335_CR50","doi-asserted-by":"publisher","first-page":"e1638","DOI":"10.1371\/journal.pone.0001638","volume":"3","author":"MG Cottingham","year":"2008","unstructured":"Cottingham MG, Andersen RF, Spencer AJ, Saurya S, Furze J, Hill AV, Gilbert SC: Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS One 2008, 3: e1638. 10.1371\/journal.pone.0001638","journal-title":"PLoS One"},{"key":"2335_CR51","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.virol.2010.08.016","volume":"407","author":"DR Smith","year":"2010","unstructured":"Smith DR, Steele KE, Shamblin J, Honko A, Johnson J, Reed C, Kennedy M, Chapman JL, Hensley LE: The pathogenesis of Rift Valley fever virus in the mouse model. Virology 2010, 407: 256-267. 10.1016\/j.virol.2010.08.016","journal-title":"Virology"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-10-349.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T07:08:12Z","timestamp":1597129692000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/1743-422X-10-349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2335"],"URL":"https:\/\/doi.org\/10.1186\/1743-422x-10-349","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12]]},"article-number":"349"}}